 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Cidera Therapeutics
CTDX
conference date: February 25, 2021 press release only.
Coverage of Cidera has not yet begun, though I started buying the stock in March 2021.
| 2021 | |||
| Cidera Therapeutics Q1 2021 Press Release | |||
| May 13, 2021 | |||
Cidera Therapeutics (CTDX) is a clinical-stage biotechnology company specializing in therapies for viral and fungal infections.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| DRNA |
| EPZM |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| ISRG |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SGEN |
| VBLT |
| VSTM |
| XLRN |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2021 William P. Meyers